- Origin Therapeutics’ (ORIG) received FDA approval for the psilocybin trial IND application
- Xpira develops psychedelic medicines for the treatment of eating disorders
- Xpira is starting Phase 2a clinical trials to study the efficacy of psilocybin-assisted therapy
- Origin Therapeutics (ORIG) is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector
- Origin Therapeutics (ORIG) is unchanged today, trading at C$0.06 at 2:25 pm ET
Origin Therapeutics’ (ORIG) company, Xpira Pharmaceuticals, receives FDA approval for psilocybin for a trial IND application.
One of its portfolio companies, Xpira Pharmaceuticals, is receiving approval from the U.S. FDA for its first Investigational New Drug (IND) application.
Xpira develops psychedelic medicines for the treatment of eating disorders, particularly for patients who have not responded well to conventional therapies. Xpira is starting Phase 2a clinical trials. This entails studying the efficacy of psilocybin-assisted therapy in patients diagnosed with Anorexia Nervosa.
Anorexia Nervosa is a deadly mental illness and currently has no approved therapeutic regimen. Xpira aims to create a successful treatment plan for patients with the disorder.
Alexander Somjen, CEO of Origin Therapeutics, says:
“With FDA approval for its IND application, Xpira has cleared a major hurdle on the path to development – and, ultimately, commercialization – of a new treatment for Anorexia Nervosa. We have full confidence in the team at Xpira and can’t wait to see what this next phase of clinical trials will bring.”
Origin Therapeutics (ORIG) is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector.
Origin Therapeutics (ORIG) is unchanged today, trading at C$0.06 at 2:25 pm ET.
